These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 26357850)

  • 1. Are Th17 cells and their cytokines a therapeutic target in Guillain-Barré syndrome?
    Wu X; Wang J; Liu K; Zhu J; Zhang HL
    Expert Opin Ther Targets; 2016; 20(2):209-22. PubMed ID: 26357850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Th1/Th2/Th17/Treg cytokines in Guillain-Barré syndrome and experimental autoimmune neuritis.
    Zhang HL; Zheng XY; Zhu J
    Cytokine Growth Factor Rev; 2013 Oct; 24(5):443-53. PubMed ID: 23791985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Th17 cells and their cytokines serve as potential therapeutic target in experimental autoimmune neuritis.
    Liu S; Liu Y; Xiao Z; Pan S; Gong Q; Lu Z
    Brain Behav; 2019 Dec; 9(12):e01478. PubMed ID: 31742934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitigated Tregs and augmented Th17 cells and cytokines are associated with severity of experimental autoimmune neuritis.
    Wang X; Zheng XY; Ma C; Wang XK; Wu J; Adem A; Zhu J; Zhang HL
    Scand J Immunol; 2014 Sep; 80(3):180-90. PubMed ID: 24910360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can IFN-γ be a therapeutic target in Guillain-Barré syndrome?
    Zhang HL; Wu L; Wu X; Zhu J
    Expert Opin Ther Targets; 2014 Apr; 18(4):355-63. PubMed ID: 24479493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The therapeutic effects of ginkgolides in Guillain-Barré syndrome and experimental autoimmune neuritis.
    Li C; Liu S; Aerqin Q; Shen D; Wu X; Liu K
    J Clin Neurosci; 2021 May; 87():44-49. PubMed ID: 33863532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor necrosis factor-α in Guillain-Barré syndrome, friend or foe?
    Wang Y; Zhang J; Luo P; Zhu J; Feng J; Zhang HL
    Expert Opin Ther Targets; 2017 Jan; 21(1):103-112. PubMed ID: 27817222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atorvastatin ameliorates experimental autoimmune neuritis by decreased Th1/Th17 cytokines and up-regulated T regulatory cells.
    Li XL; Dou YC; Liu Y; Shi CW; Cao LL; Zhang XQ; Zhu J; Duan RS
    Cell Immunol; 2011; 271(2):455-61. PubMed ID: 21889126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Th17 helper cell and T-cell immunoglobulin and mucin domain 3 involvement in Guillain-Barré syndrome.
    Liang SL; Wang WZ; Huang S; Wang XK; Zhang S; Wu Y
    Immunopharmacol Immunotoxicol; 2012 Dec; 34(6):1039-46. PubMed ID: 22738814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roles of macrophage migration inhibitory factor in Guillain-Barré syndrome and experimental autoimmune neuritis: beneficial or harmful?
    Shen D; Lang Y; Chu F; Wu X; Wang Y; Zheng X; Zhang HL; Zhu J; Liu K
    Expert Opin Ther Targets; 2018 Jul; 22(7):567-577. PubMed ID: 29856236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial or Harmful Role of Macrophages in Guillain-Barré Syndrome and Experimental Autoimmune Neuritis.
    Shen D; Chu F; Lang Y; Geng Y; Zheng X; Zhu J; Liu K
    Mediators Inflamm; 2018; 2018():4286364. PubMed ID: 29853789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bowman-Birk inhibitor concentrate suppresses experimental autoimmune neuritis via shifting macrophages from M1 to M2 subtype.
    Jin T; Yu H; Wang D; Zhang H; Zhang B; Quezada HC; Zhu J; Zhu W
    Immunol Lett; 2016 Mar; 171():15-25. PubMed ID: 26791957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoimmunity and cytokines in Guillain-Barré syndrome revisited: review of pathomechanisms with an eye on therapeutic options.
    Ebrahim Soltani Z; Rahmani F; Rezaei N
    Eur Cytokine Netw; 2019 Mar; 30(1):1-14. PubMed ID: 31074417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. M1 Macrophage Derived Exosomes Aggravate Experimental Autoimmune Neuritis via Modulating Th1 Response.
    Du T; Yang CL; Ge MR; Liu Y; Zhang P; Li H; Li XL; Li T; Liu YD; Dou YC; Yang B; Duan RS
    Front Immunol; 2020; 11():1603. PubMed ID: 32793234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Celastrol attenuates Guillain-Barré syndrome by inhibiting TLR4/NF-κB/STAT3 pathway-mediated Th1/Th17 cell differentiation.
    Shao H; Fan W; Tang Y
    Gen Physiol Biophys; 2023 Jan; 42(1):13-24. PubMed ID: 36705301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roles of T helper 17 cells and interleukin-17 in neuroautoimmune diseases with emphasis on multiple sclerosis and Guillain-Barré syndrome as well as their animal models.
    Wang X; Ma C; Wu J; Zhu J
    J Neurosci Res; 2013 Jul; 91(7):871-81. PubMed ID: 23653308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Class I PI3K inhibitor ZSTK474 attenuates experimental autoimmune neuritis by decreasing the frequency of Th1/Th17 cells and reducing the production of proinflammatory cytokines.
    Chen X; Guo Y; Han R; Liu H; Ding Y; Shi Y; Kong D; Ma X
    Cell Immunol; 2018 Jul; 329():41-49. PubMed ID: 29724464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence of altered Th17 pathway signatures in the cerebrospinal fluid of patients with Guillain Barré Syndrome.
    Debnath M; Nagappa M; Dutta D; Talukdar PM; Subbanna M; Shivakumar V; Wahatule R; Sinha S; Bindu PS; Periyavan S; Umamaheswara Rao GS; Kumar MA; Taly AB
    J Clin Neurosci; 2020 May; 75():176-180. PubMed ID: 32217048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-23/IL-17 immune axis in Guillain Barré Syndrome: Exploring newer vistas for understanding pathobiology and therapeutic implications.
    Debnath M; Nagappa M; Murari G; Taly AB
    Cytokine; 2018 Mar; 103():77-82. PubMed ID: 29331587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P2X7 receptor antagonists modulate experimental autoimmune neuritis via regulation of NLRP3 inflammasome activation and Th17 and Th1 cell differentiation.
    Xie Y; Han R; Li Y; Li W; Zhang S; Wu Y; Zhao Y; Liu R; Wu J; Jiang W; Chen X
    J Neuroinflammation; 2024 Mar; 21(1):73. PubMed ID: 38528529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.